Trial reportBreast cancer research and treatment1996
Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer.
Trial report in Breast cancer research and treatment, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.Circulation · 2018Pooled it
- Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies:JACC. CardioOncology · 2023Review
- Review
- Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study.Breast cancer research and treatment · 2022Article
- Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.Heart (British Cardiac Society) · 2021Article
- Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.Biochimica et biophysica acta · 2015Review
- Apolipoprotein E genetic polymorphism, serum lipoprotein levels and breast cancer risk: A case-control study.Molecular and clinical oncology · 2014Article
- Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy.Medical oncology (Northwood, London, England) · 2011Article
- Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.Journal of cancer research and clinical oncology · 2006Review
- Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer.Breast care (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum lipids and apolipoprotein levels were measured in twenty postmenopausal women with primary breast cancer, before and three months after tamoxifen therapy (10 mg twice a day). Tamoxifen caused a significant reduction in total serum cholesterol (10%; P < 0.02), and in low-density lipoprotein cholesterol (17%; P < 0.01), and a significant 47% increase in the subclass 2 of the high density lipoprotein cholesterol (P < 0.01). In addition, tamoxifen caused a 16% increase in apolipoprotein A-I, a 12% decrease in apolipoprotein B (P < 0.05), and a 37% reduction in the serum concentration of lipoprotein (a) (P < 0.01). These results show that tamoxifen brings about an important improvement in serum lipid profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.